Wall Street still prices Abbott like a dividend stalwart, but overlooked moves suggest that framing may be costing investors ...
Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes.
DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with ...
Health Canada has granted authorisation for the Dexcom G7 15 Day continuous glucose monitor (CGM) for adults aged 18 years ...
Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the ...
Healthy influencers are embracing a wearable once reserved for diabetes patients to optimize their health. But experts say ...
Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, today announces that DBLG2 ...
Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor (CGM) through Heald will now receive complimentary ...
The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of ...
Smartwatches still can’t measure blood sugar on their own, but AI-powered CGMs are changing how glucose data is tracked and ...
Zacks Investment Research on MSN
Here's why you should retain DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI coaching and other app-based features.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results